BRCA (Breast cancer early onset)

P=N/A, N=50, Recruiting, Institute of Cancer Research, United Kingdom | Trial completion date: Dec 2030 --> Dec 2032 | Trial primary completion date: Dec 2030 --> Dec 2027

Our findings establish MAP3K1 and MAP2K4 as key tumor suppressors in BRCA that operate via the JNK2-p53-FOSL1 axis. Their inactivation provides an alternative mechanism for p53 pathway disruption, adhering to the "minimal necessary alteration" principle in cancer signaling. This study highlights the dual regulatory mechanisms controlling FRA1 expression and offers insights into breast cancer heterogeneity, with potential implications for targeted therapy and patient stratification.

PARPi + NHA represent a significant advance in mCRPC therapy. Molecular genetic testing for HRR mutations, especially BRCA 1/2, is crucial for treatment planning.

To overcome foundation model constraints, approaches like model distillation, weak supervision, and modular training are critically examined. Progress now depends on high-quality datasets, rigorous multi-institutional validation, and collaboration between computational scientists, clinicians, and regulators to deliver explainable, clinically actionable innovations in breast cancer.

BRCA2 cancers tended to present with more advanced features, while BRCA1 cancers were more often detected at earlier stage. These findings underscore the value of BRCA testing not only for PARP inhibitor eligibility but also for subtype-specific risk assessment and individualized preventive strategies.

For CPM, independent predictors included age (OR = 0.983, 95% CI: 0.968-0.999, P = .039) and prior counseling on genetic risk (OR = 1.576, 95% CI: 1.035-2.401, P = .034). Professional genetic counseling and celebrity influence are key determinants of breast cancer patients' awareness of BRCA testing and uptake of risk-reducing surgery, underscoring the need for clinicians to integrate these factors into patient-centered decision-making.

GDI1 is highly expressed in BRCA and is significantly associated with poor patient prognosis. Its expression level influences the tumor immune microenvironment, and low methylation status indicates worse clinical outcomes. These findings suggest that GDI1 may serve as a potential biomarker for prognosis assessment and immune regulation in BRCA, providing new directions for targeted therapy.

P2, N=40, Not yet recruiting, AHS Cancer Control Alberta | Trial primary completion date: Jul 2027 --> Apr 2028

The present findings are from a limited number of heterogenous studies and hence must be interpreted with caution. https://www.crd.york.ac.uk/prospero/, identifier CRD42025641361.

A total of 44 manuscripts were retrieved, with only two articles reporting data on pregnancy with vitrified oocytes after fertility-sparing surgery, and 3 cases included. Whilst more research is required for assisted reproductive technology and ovarian cancer, and for the elucidation of the role of BRCA mutations on fertility, the present report aims to provide impetus to further research in this field.

This benefit was confirmed in a multivariable analysis, supporting PARPi as the preferred option in eligible patients. Our findings suggest that PARPi should be prioritized in the post-CDK4/6i treatment sequence for BRCA LP/PV carriers with HR+/HER2 aBC and highlight the critical role of germline BRCA testing.

Notably, the BET inhibitor mivebresib (ABBV-075) significantly improved survival rates by 50% in a metastatic UM xenograft mouse model and prevented detectable metastases in the bones, spinal cord, and brain...BET and HDAC inhibitors reversed gene expression signatures associated with high metastatic risk and induced a neuron-like phenotype in UM cells. These findings establish BET inhibition as a potent and previously underappreciated vulnerability for metastatic UM.